

Docket No.

248320US0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Susumu KITANAKA, et al.

SERIAL NO: 10/767,436

GAU:

FILED: January 30, 2004

FOR: NOVEL DITERPENE COMPOUNDS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon

Frederick D. Vastine


Registration No. 27,013

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Vincent K. Shier, Ph. D.
Registration Number 50,552

Form PTO 1449 (Modified)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 248320US0	SERIAL NO. 10/767,436
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT Susumu KITANAKA, et al.	
		FILING DATE January 30, 2004	GROUP
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)			
	AAA	S. MORRIS KUPCHAN, et al., Science, Vol. 191, pages 571-572, "ANTILEUKEMIC PRINCIPLES ISOLATED FROM EUPHORBIAACEAE PLANTS", February 1976	
	AAK	TIAN-SHUNG WU, et al., Journal of Natural Products, Vol. 54, No. 3, pages 823-829, "ANTITUMOR AGENTS, 119'. KANSUIPHORINS A AND B, TWO NOVEL ANTILEUKEMIC DITERPENE ESTERS FROM <i>EUPHORBIA KANSUI</i> ", May-June 1991	
	AAC	MAGDALENA BLANCO-MOLINA, et al., Chemistry & Biology 8/8, pages 767-778, "INGENOL ESTERS IDUCE APOPTOSIS IN JURKAT CELLS THROUGH AN AP-1 AND NF- κ B INDEPENDENT PATHWAY", 2001	
	AAD	LI-YAN WANG, et al., "A STUDY FOR BIOLOGICALLY ACTIVE COMPOUNDS EXTRACTED FROM <i>EUPHORBIA KANSUI</i> L. (3)", (http://202.209.162.53/123/1/multifinder.asp), February 1, 2003	
	AAE	LI-YAN WANG, et al., Journal of Natural Products, Vol. 65, No. 9, pages 1246-1251, "DITERPENES FROM THE ROOTS OF <i>EUPHORBIA KANSUI</i> AND THEIR IN VITRO EFFECTS ON THE CELL DIVISION OF <i>XENOPUS</i> ", 2002	
	AAF	LI-YAN WANG, et al., Chem. Pharm. Bull. 51(8), pages 935-941, "DITERPENES FROM THE ROOTS OF <i>EUPHORBIA KANSUI</i> AND THEIR IN VITRO EFFECTS ON THE CELL DIVISION OF <i>XENOPUS</i> (2) ^{1,2} ", 2003	
	AAC	HISASHI MATSUDA, et al., Bioorganic & Medicinal Chemistry 11, pages 1995-2000, "STRUCTURAL REQUIREMENTS OF FLAVONOIDS FOR NITRIC OXIDE PRODUCTION INHIBITORY ACTIVITY AND MECHANISM OF ACTION", 2003	
	AAH	HUI-YI LIN, et al., Biochemical Pharmacology 66, pages 1821-1832, "INHIBITION OF LIPOPOLYSACCHARIDE-INDUCED NITRIC OXIDE PRODUCTION BY FLAVONOIDS IN RAW264.7 MACROPHAGES INVOLVES HEME OXYGENASE-1", 2003	
	AAI	JUDIT HOHMANN, et al., Journal of Natural Products, Vol. 60, No. 4, pages 331-335, "MACROCYCLIC DITERPENE POLYESTERS OF THE JATROPHANE TYPE FROM <i>EUPHORBIA ESULA</i> ", 1997	
	AAJ	PETER LORENZ, et al., Nitric Oxide 9, pages 64-76, "OXYRESVERATROL AND RESVERATROL ARE POTENT ANTIOXIDANTS AND FREE RADICAL SCAVENGERS: EFFECTS ON NITROSATIVE AND OXIDATIVE STRESS DERIVED FROM MICROGLIAL CELLS", 2003	
	AAK	GIUSEPPINA AUTORE, et al., Life Sciences 70, pages 523-534, "INHIBITION OF NITRIC OXIDE SYNTHASE EXPRESSION BY A METHANOLIC EXTRACT OF <i>CRESCENTIA ALATA</i> AND ITS DERIVED FLAVONOLS", 2001	
	AAL	HEE KEE KIM, et al., Biochemical Pharmacology, Vol. 58, pages 759-765, "EFFECTS OF NATURALLY OCCURRING FLAVONOIDS ON NITRIC OXIDE PRODUCTION IN THE MACROPHAGE CELL LINE RAW 264.7 AND THEIR STRUCTURE-ACTIVITY RELATIONSHIPS", 1999	
	AAM	BERNADET P. DA SILVA, et al., Phytochemistry 53, pages 87-92, "FLAVONOL GLYCOSIDES FROM <i>COSTUS SPICATUS</i> ", 2000	
	AAN		
	AAO		
	AAP		
	AAQ		
Examiner		Date Considered	
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			